P028: Confronting Barriers in HER2-Positive Metastatic Breast Cancer: Insights from a Phase II Trial of Inetetamab, Pyrotinib, and Chemotherapy

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2025-02-01 DOI:10.1016/j.breast.2025.103915

J. Zhao, Z. Zhou, L. Ding, J. Ye, T. Long, G. Zou, Y. Cai, J. Chai, H. Yao, Y Wang

引用次数: 0

查看原文本刊更多论文

P028：面对her2阳性转移性乳腺癌的障碍：来自Inetetamab， Pyrotinib和化疗的II期试验的见解

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.